NASDAQ:ALZN

Alzamend Neuro Stock Insider Trading

Healthcare > Biotechnology

Buy ALZN

*Your capital is at risk

$1.31

-0.0400 (-2.96%)

At Close: Jul 31, 2026

Alzamend Neuro Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -91.83. In total, the insiders bought 1.99M and sold 1.82M ALZN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-91.83
● Buy	1.99M shares
● Sell	1.82M shares
31% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Apr 14, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -91.83. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 22, 2025 Buy	Common Stock C-Conversion	Ault Milton C Iii	Director	100 000 Value: $232.0K
Sep 22, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Ault Milton C Iii	Director	232 Value: $538
Sep 22, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Ault Milton C Iii	Director	232 Value: $538
Sep 22, 2025 Buy	Common Stock C-Conversion	Ault Milton C Iii	Director	100 000 Value: $232.0K
Sep 19, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	77 009 Value: $180.9K
Sep 19, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	77 009 Value: $180.9K
Sep 18, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	20 870 Value: $51.5K
Sep 18, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	20 870 Value: $51.5K
Sep 17, 2025 Buy	Common Stock C-Conversion	Ault Milton C Iii	Director	100 000 Value: $232.0K
Sep 17, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	2 121 Value: $5K
Sep 17, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Ault Milton C Iii	Director	232 Value: $538
Sep 17, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Ault Milton C Iii	Director	232 Value: $538
Sep 17, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	2 121 Value: $5K
Sep 17, 2025 Buy	Common Stock C-Conversion	Ault Milton C Iii	Director	100 000 Value: $232.0K
Jul 31, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	100 000 Value: $221.6K
Jul 31, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	100 000 Value: $221.6K
Jul 30, 2025 Buy	Common Stock C-Conversion	Ault Milton C Iii	Director	100 000 Value: $232.0K
Jul 30, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	29 449 Value: $74.0K
Jul 30, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Ault Milton C Iii	Director	232 Value: $538
Jul 30, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Ault Milton C Iii	Director	232 Value: $538
Jul 30, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	29 449 Value: $74.0K
Jul 30, 2025 Buy	Common Stock C-Conversion	Ault Milton C Iii	Director	100 000 Value: $232.0K
Jul 28, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	8 311 Value: $22.3K
Jul 28, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	8 311 Value: $22.3K
Jul 25, 2025 Sell	Common Stock S-Sale	Ault Milton C Iii	Director	36 532 Value: $105.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALZAMEND NEURO, INC.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutan...

Read Full Profile Here